ClinicalTrials.gg
Not yet recruitingNCT07901257Updated Oct 28, 2026

Social Software-Based Intelligent Management System for Bowel Preparation

An interventional study of AI-assisted Bowel Preparation Management and Conventional Bowel Preparation Management in Colorectal Polyp, Colorectal Adenoma and Bowel Preparation, sponsored by Shandong University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by Shandong University · Not applicable, Interventional, and Diagnostic

Updated Oct 28, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
740
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Colorectal cancer (CRC) is one of the most common malignancies worldwide, and colonoscopy is an important method for CRC screening and early detection. The effectiveness of colonoscopy is closely related to the quality of bowel preparation. However, inadequate patient understanding and poor adherence to bowel preparation instructions may reduce preparation quality.

This randomized controlled trial aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted bowel preparation management system based on WeChat in patients undergoing colonoscopy. Participants will be randomly assigned to either an intervention group receiving AI-assisted bowel preparation guidance and management through WeChat or a control group receiving conventional bowel preparation education and management.

The study will compare bowel preparation quality between the two groups and assess whether AI-assisted management can improve patients' adherence to bowel preparation instructions and the overall effectiveness of bowel preparation.

02

Conditions studied

  • Colorectal Polyp
  • Colorectal Adenoma
  • Bowel Preparation
  • Artificial Intelligence

Browse trials for

Keywords

  • Colorectal Polyp;Colorectal Adenoma;Bowel Preparation;AI
03

In context

Polyps

312 studies on the registry are indexed under Polyps; 60 are open to participants now.

This study's planned enrollment of 740 is above the median of 150 across 204 interventional studies indexed under Polyps.

Browse Polyps studies →

Lead sponsor

Shandong University is the lead sponsor of 292 studies on the registry; 60 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Outpatients aged 18-75 years.
  • Patients or family members living with the patients are able to use a smartphone and WeChat.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of colorectal surgery.
  • Patients with colonic stenosis, obstructive tumors, or toxic megacolon.
  • Patients with symptoms or imaging findings suggestive of gastrointestinal obstruction.
  • Patients with severe cardiac, pulmonary, or renal dysfunction.
  • Patients who are pregnant or breastfeeding.
  • Patients with an allergy to laxatives.
  • Patients with electrolyte disturbances.
  • Patients unable to provide written .
  • Patients who cancel the endoscopic examination for any reason or fail to complete the colonoscopy.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
740 participants (estimated)

Study arms

  • Experimental
    AI-assisted Bowel Preparation Management

    Participants assigned to the intervention group will receive AI-assisted bowel preparation guidance and management through WeChat in addition to standard bowel preparation.

    Behavioral: AI-assisted Bowel Preparation Management

  • Active comparator
    Conventional Bowel Preparation Management

    Participants in this group will receive conventional bowel preparation education and management according to routine clinical practice before colonoscopy.

    Behavioral: Conventional Bowel Preparation Management

Interventions

  • BehavioralAI-assisted Bowel Preparation Management

    Participants assigned to the intervention group will receive AI-assisted bowel preparation guidance and management through WeChat in addition to standard bowel preparation. The system provides guidance and support throughout the bowel preparation process before colonoscopy.

  • BehavioralConventional Bowel Preparation Management

    Participants assigned to the control group will receive conventional bowel preparation education and management according to routine clinical practice before colonoscopy.

06

What researchers measure

Primary outcomes

  1. Bowel Preparation Quality Assessed by the Boston Bowel Preparation Scale (BBPS)

    Bowel preparation quality will be assessed using the Boston Bowel Preparation Scale (BBPS). The total BBPS score ranges from 0 to 9. Excellent bowel preparation is defined as a total BBPS score ≥8. Adequate bowel preparation is defined as a total BBPS score ≥6, with a score ≥2 in each colonic segment.

    Time frame: During colonoscopy.

Secondary outcomes

  1. Polyp Detection Rate (PDR)

    Polyp detection rate is defined as the proportion of participants in whom at least one colorectal polyp is detected during colonoscopy.

    Time frame: During colonoscopy.

  2. Adenoma Detection Rate (ADR)

    Adenoma detection rate is defined as the proportion of participants in whom at least one histologically confirmed colorectal adenoma is detected during colonoscopy.

    Time frame: From colonoscopy to completion of histopathological assessment.

  3. Cecal Intubation Rate

    Cecal intubation rate is defined as the proportion of colonoscopy procedures in which the colonoscope successfully reaches the cecum.

    Time frame: During colonoscopy.

  4. Insertion Time

    Insertion time is defined as the time from insertion of the colonoscope through the anus to successful intubation of the cecum.

    Time frame: During colonoscopy.

  5. Withdrawal Time

    Withdrawal time is defined as the time from the start of colonoscope withdrawal from the cecum to complete removal of the colonoscope.

    Time frame: During colonoscopy.

  6. Patient Satisfaction

    Patient satisfaction with bowel preparation education and management will be assessed after completion of bowel preparation using the study-specific satisfaction questionnaire or rating scale.

    Time frame: Day 1 (After completion of bowel preparation and before colonoscopy)

  7. Patient Tolerance

    Patient tolerance of bowel preparation will be assessed based on sleep quality during bowel preparation and willingness to undergo the same bowel preparation regimen again in the future.

    Time frame: Day 1 (After completion of bowel preparation and before colonoscopy)

  8. Bowel Preparation-related Discomfort Symptoms checklist

    Bowel preparation-related discomfort symptoms, including abdominal pain, abdominal distension, nausea, vomiting, and other adverse symptoms, will be recorded after completion of bowel preparation.

    Time frame: Day 1 (From the start of bowel preparation to colonoscopy)

07

Study locations

1 site
08

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07901257
Responsible party
Xiuli Zuo (Director of Gastroenterology Department, Qilu Hospital of Shandong University) — Principal investigator
First posted
Oct 28, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Feb 28, 2028 (estimated)
Completion
Apr 30, 2028 (estimated)
Last update
Oct 28, 2026

Study contacts

Xiuli Zuo, Professor,MD,PhD
Contact
zuoxiuli@sdu.edu.cn
86+18560080066

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion